Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR17031 vs INS068 vs SHR20004 in type 2 diabetes mellitus
CTR20220857Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HR17031 in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Apr 2022; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20220857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220857.